AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BioFish Holding AS

M&A Activity Jun 2, 2025

3558_rns_2025-06-02_0c660210-36c3-4ffc-93f6-a4579745ca9b.html

M&A Activity

Open in Viewer

Opens in native device viewer

BIOFISH HOLDING AS - The Board of Directors concludes the strategic review and recommends an offer from Langøylaks to acquire all shares and warrants

BIOFISH HOLDING AS - The Board of Directors concludes the strategic review and recommends an offer from Langøylaks to acquire all shares and warrants

Ljones, 2 June 2025: The Board of Directors of Biofish Holding AS (the

"Company" or "BioFish") today announces that it has entered into a transaction

agreement with Langøylaks Holding 2 AS ("Langøylaks" or the "Offeror")

regarding a recommended voluntary cash tender offer to acquire all outstanding

shares and warrants in the Company (the "Offer").

Highlights

* BioFish shareholders and/ or warrantholders to recieve NOK 1.77 per share,

and NOK 0.47 per warrant ("the Offer price"), to be settled in cash.

* The Offer represents a total consideration to shareholders of BioFish of

approximately NOK 230 million to be allocated to a total of 111,978,666

shares and 67,521,334 warrants.

* The Offer price represents a premium of 45.1 per cent to the last trading

price of NOK 1.22 as of 10 January 2025, the last trading day before the

announcement of the strategic review.

* The Offer price represents a premium of 19.5 per cent to the last 3 months

VWAP of NOK 1.48 as per 30 May 2025.

* The Offeror has secured sufficient funding to finance the transaction and

the Offer is not subject to any financing condition.

* The Board and management unanimously supports and recommends the Offer

* Completion of the Offer is subject to fulfilment or waiver by the Offeror of

customary closing conditions, including but not limited to shareholders and

warrant holders representing more than 90 per cent of the shares on a fully

diluted basis having accepted the Offer.

Board recommendation and pre-acceptances

The Offer is the result of a strategic review authorised by the Company's

Board of directors (the "Board"), as announced 13 January 2025. The Board has

unanimously resolved to recommend that shareholders of the Company accept the

Offer.

"The Board has conducted a thorough strategic review involving discussions

with a wide range of stakeholders and has considered different offers from

strategic and financial players. The Board is confident that the Offer price

represents a fair reflection of today's values and believe Langøylaks will be

good owners and partners for BioFish. We unanimously recommend that

shareholders accept the proposed offer", said Thorbjørn Gjelsvik, chair of the

Board.

Shareholders and warrantholders representing a total of 52.42 per cent of the

shares (on a fully diluted basis) have given pre-acceptances where they have

undertaken to accept the Offer. Shareholders who have undertaken to accept the

Offer include the Company's largest shareholders, Awilco AS, Odfjell Land AS,

Stoksund AS and Biofish Aquafarm AS, owning shares and warrants in BioFish

constituting 15.09 per cent, 8.84 per cent, 10.38 per cent and 10.39 per cent

of the BioFish shares (on a fully diluted basis), respectively, as well as

other shareholders, including the CEO and the CFO, representing a total of

7.72 per cent of the shares (on a fully diluted basis).

As part of the pre-acceptances, the pre-accepting shareholders have undertaken

not to solicit or accept alternative offers for the Company, capital

injections or investments in the Company or any other Group company. The

pre-acceptances are binding and irrevocable.

The Offeror

Langøylaks is a Norwegian salmon farmer based in Austevoll with production in

production areas PO3 and PO4. With over 45 years of industry experience,

Langøylaks has built a strong foundation in sustainable salmon farming.

Langøylaks is privately owned by people with solid industry experience who is

actively involved in the Offeror's operations. Driven by good operations and

strong partnerships, Langøylaks has produced salmon and delivered solid

financial results for many years.

"After a comprehensive evaluation of BioFish, Langøylaks is confident that

this partnership represents an excellent strategic fit. We see strong

potential for mutual growth, with significant synergies across both production

and expertise. This collaboration will strengthen both companies and create

exciting opportunities moving forward," said Johannes Møgster, CEO of

Langøylaks.

Strategic rationale

Langøylaks and BioFish represent a strong strategic fit. Both businesses are

strategically located on Norway's west coast, which provides a solid platform

for future scalability.

With Langøylaks as a new, industrial owner and partner, BioFish is well

positioned to develop its position as a reliable supplier of high-quality,

healthy smolt and post-smolt. BioFish will also benefit from becoming a member

of the Salmon Group, giving access to more attractive purchasing agreements as

well as an exchange of experience and knowledge.

For the Offeror, access to BioFish's high-quality smolt and post-smolt

provides a strong platform to improve biological performance in the sea phase

of its operations and supports future growth ambitions. The addition of

BioFish to its integrated value chain may entail operational advantages,

including a more secure supply of smolt, and potential scale benefits, as well

as access to the certified organic production offered by BioFish.

Key terms of the Offer

Pursuant to the Offer, the shareholders of the Company will be offered NOK

1.77 per share, and NOK 0.47 per warrant, to be settled in cash upon

completion of the Offer.

The Offer price implies a total consideration for all the shares and warrants

of approximately NOK 230 million, based on 111,978,666 shares outstanding and

67,521,334 warrants issued.

The complete terms and conditions of the Offer will be set out in an official

document (the "Offer Document") to be sent to BioFish's shareholders. The

Offer Document is expected to be sent, and the offer period is expected to

begin, during June 2025.

The initial acceptance period will commence following the publication of the

Offer Document and is expected to last for 2 weeks, subject to any extensions

up to a maximum offer period of 10 weeks.

As will be further detailed and specified in the Offer Document, completion of

the Offer will be subject to the following conditions being satisfied or

waived in whole or in part by the Offeror:

* shareholders of the Company representing more than 90 per cent of the issued

and outstanding share capital and voting rights of Company on a fully

diluted basis (as defined in the Offer Document) having validly accepted the

Offer;

* the Board shall not have amended or withdrawn its unanimous recommendation

of the Offer;

* the Company shall conduct its business in the ordinary course of business in

all material respects;

* no Material Adverse Change (as defined in the Offer Document) shall have

occurred between the date of the Transaction Agreement and until settlement

of the Offer;

* no material breach by the Company of the Transaction Agreement shall have

occurred; and

* no court or governmental or regulatory authority of any competent

jurisdiction shall have taken any form of legal action that will restrain or

prohibit the consummation of the Offer.

In the absence of unforeseen circumstances, the Offer is anticipated to be

completed in Q2 or Q3 2025.

If, as a result of the Offer or otherwise, the Offeror acquires and holds

Shares representing 90 per cent or more of the total issued Shares and voting

rights in the Company (on a fully diluted basis), then the Offeror intends to

initiate a compulsory redemption (squeeze-out) of the remaining Shares not

already owned by the Offeror. Also, if, as a result of the Offer or otherwise,

the Offeror holds a sufficient majority of the Shares, the Offeror intends to

propose to the general meeting of the Company that an application is filed

with the Oslo Stock Exchange for the delisting of the Shares from Euronext

Growth Oslo.

Advisers:

Pareto Securities AS is acting as financial advisor and Advokatfirmaet Haavind

AS is acting as legal advisor to the Company. Advokatfirmaet Wiersholm AS is

acting as legal advisor to the Offeror.

Contacts

Sondre Hagerup Johnsrud, CEO of Biofish Holding AS

Mob: +47 975 79 321 Email: [email protected]

Johnny Duedahl, CFO of Biofish Holding AS

Mob: +47 982 06 833 Email: [email protected]

Johannes Møgster, CEO of Langøylaks AS

Mob: +47 452 35 896 Email: [email protected]

About BioFish

BioFish is a Norwegian independent producer of high-quality smolt and

post-smolt. The Company has a RAS production facility in Ljones close to the

Hardangerfjord on the west coast of Norway. Numerous Norwegian fish farming

sites are located within one day of transport.

***

This information is considered to constitute inside information pursuant to

the EU Market Abuse Regulation and is subject to the disclosure requirements

pursuant to section 5-12 of the Norwegian Securities Trading Act. The

information was submitted for publication, by the Biofish Holding contact

person set out above on 2 June 2025 at 0745 CET.

The Offer and the distribution of this announcement and other information in

connection with the Offer may be restricted by law in certain jurisdictions.

When published, the Offer Document and related acceptance forms will not and

may not be distributed, forwarded or transmitted into or within any

jurisdiction where prohibited by applicable law, including without limitation,

Canada, Australia, New Zealand, South Africa, Hong Kong and Japan. The Offeror

does not assume any responsibility in the event there is a violation by any

person of such restrictions. Persons into whose possession this announcement

or such other information should come are required to inform themselves about

and to observe any such restrictions.

This announcement is not a tender offer document and, as such, does not

constitute an offer or the solicitation of an offer to acquire the Shares.

Investors may accept the Offer only on the basis of the information provided

in the Offer Document. Offers will not be made directly or indirectly in any

jurisdiction where either an offer or participation therein is prohibited by

applicable law or where any tender offer document or registration or other

requirements would apply in addition to those undertaken in Norway.

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR Article 17. The information was submitted for publication at

2025-06-02 07:45 CEST.

Talk to a Data Expert

Have a question? We'll get back to you promptly.